Abstract
The development of successful antitumor immunity depends upon cross talk and collaboration between multiple T cell and antigen-presenting cell subsets. In this chapter, we review and summarize current knowledge regarding the function, interactions, and prognostic significance of each of these populations, as well as their dependence upon one another within the tumor microenvironment.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Freedman LR, Cerottini JC, Brunner KT (1972) In vivo studies of the role of cytotoxic T cells in tumor allograft immunity. J Immunol 109:1371–1378
Clark WH Jr, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, Synnestvedt M et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893–1904
Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE (2003) Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 10:309–313
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586–2593
Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY (2006) Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 132:293–301
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538–18543
Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932–3936
Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, Lopez-Soto A, Fernandez-Guizan A, Acebes-Huerta A, Gonzalez-Huerta AJ et al (2010) Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma 51:1829–1836
Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310
Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM et al (2006) Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55:451–458
Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1456
Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ (1998) How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 10:581–587
Cullen SP, Martin SJ (2008) Mechanisms of granule-dependent killing. Cell Death Differ 15:251–262
Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity. Cell Death Differ 17:616–623
Rothstein TL, Mage M, Jones G, McHugh LL (1978) Cytotoxic T lymphocyte sequential killing of immobilized allogeneic tumor target cells measured by time-lapse microcinematography. J Immunol 121:1652–1656
Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P et al (1996) Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791–13796
Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63:4095–4100
Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT et al (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981–992
Celada A, Gray PW, Rinderknecht E, Schreiber RD (1984) Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 160:55–74
Schreiber RD, Celada A, Buchmeier N (1986) The role of interferon-gamma in the induction of activated macrophages. Ann Inst Pasteur Immunol 137C:203–206
Dighe AS, Richards E, Old LJ, Schreiber RD (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1:447–456
Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wigginton JM et al (2000) IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 164:231–239
Weber JS, Rosenberg SA (1988) Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48:5818–5824
Wallach D, Fellous M, Revel M (1982) Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 299:833–836
Johnson DR, Pober JS (1990) Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium. Proc Natl Acad Sci USA 87:5183–5187
Mach B, Steimle V, Martinez-Soria E, Reith W (1996) Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 14:301–331
Huse M, Lillemeier BF, Kuhns MS, Chen DS, Davis MM (2006) T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol 7:247–255
Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN (2000) Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol 156:1171–1176
Zhang B, Karrison T, Rowley DA, Schreiber H (2008) IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 118:1398–1404
Mrass P, Weninger W (2006) Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 213:195–212
Fisher DT, Chen Q, Appenheimer MM, Skitzki J, Wang WC, Odunsi K, Evans SS (2006) Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Invest 35:251–277
Mempel TR, Bauer CA (2009) Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis 26:311–327
Pittet MJ (2009) Behavior of immune players in the tumor microenvironment. Curr Opin Oncol 21:53–59
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680
Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M et al (1991) Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 83:932–937
Hamai A, Benlalam H, Meslin F, Hasmim M, Carre T, Akalay I, Janji B et al (2010) Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75:1–8
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357
Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478–480
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480–483
Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474–478
Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357–2368
Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT (1999) Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21:339–359
Hibbs JB Jr, Taintor RR, Chapman HA Jr, Weinberg JB (1977) Macrophage tumor killing: influence of the local environment. Science 197:279–282
Stuehr DJ, Nathan CF (1989) Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169:1543–1555
Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK et al (2010) Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 207:2455–2467
Kapsenberg ML, Hilkens CM, Wierenga EA, Kalinski P (1999) The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy 29(suppl 2):33–36
Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, Corthay A (2011) Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2:240
Sirianni MC, Vincenzi L, Fiorelli V, Topino S, Scala E, Uccini S, Angeloni A et al (1998) gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood 91:968–976
Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K (2005) Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13:1153–1158
Ito N, Suzuki Y, Taniguchi Y, Ishiguro K, Nakamura H, Ohgi S (2005) Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 25:2027–2031
Kondo T, Nakazawa H, Ito F, Hashimoto Y, Osaka Y, Futatsuyama K, Toma H et al (2006) Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 97:780–786
Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S (2010) Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102:742–747
Noben-Trauth N, Shultz LD, Brombacher F, Urban JF Jr, Gu H, Paul WE (1997) An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci USA 94:10838–10843
Zheng W, Flavell RA (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587–596
Kuhn R, Rajewsky K, Muller W (1991) Generation and analysis of interleukin-4 deficient mice. Science 254:707–710
Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G (1993) Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362:245–248
Pereira MC, Oliveira DT, Kowalski LP (2011) The role of eosinophils and eosinophil cationic protein in oral cancer: a review. Arch Oral Biol 56:353–358
Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, Capron M (2010) Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 185:7443–7451
Sato M, Goto S, Kaneko R, Ito M, Sato S, Takeuchi S (1998) Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res 18:3951–3955
Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC (2001) Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 167:2972–2978
Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K et al (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55:3847–3853
Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT (1995) Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 41:111–121
Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263–1271
Evans CF, Galustian C, Bodman-Smith M, Dalgleish AG, Kumar D (2010) The effect of colorectal cancer upon host peripheral immune cell function. Colorectal Dis 12:561–569
Giuntoli RL 2nd, Lu J, Kobayashi H, Kennedy R, Celis E (2002) Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8:922–931
Ziegler A, Heidenreich R, Braumuller H, Wolburg H, Weidemann S, Mocikat R, Rocken M (2009) EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 113:3494–3502
Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T (1999) T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 189:803–810
Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563–570
Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P et al (2004) Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 172:1304–1310
Marturano J, Longhi R, Russo V, Protti MP (2008) Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. Cancer Res 68:1555–1562
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM et al (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619–628
Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S et al (2003) CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol 170:1490–1497
Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E et al (2003) Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63:4481–4489
Tassi E, Gavazzi F, Albarello L, Senyukov V, Longhi R, Dellabona P, Doglioni C et al (2008) Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 181:6595–6603
De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208:469–478
Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W (2007) Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 179:1423–1426
Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149
Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C et al (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50:980–989
Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE et al (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204:1405–1416
Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE et al (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204:2473–2485
Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184:1630–1641
Liu H, Rohowsky-Kochan C (2008) Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 180:7948–7957
Barnett BG, Ruter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G et al (2008) Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol 622:255–260
Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J et al (2011) Human TH17 cells are long-lived effector memory cells. Sci Transl Med 3:104ra100
Wilke CM, Wang L, Wei S, Kryczek I, Huang E, Kao J, Lin Y et al (2011) Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med 9:217
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E et al (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204:1849–1861
Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G et al (2008) Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 205:1903–1916
Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, Raskin L et al (2009) Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 206:525–534
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK et al (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14:3254–3261
Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN et al (2010) Generation and differentiation of interleukin-17-producing CD4+ T cells in malignant pleural effusion. J Immunol 185:6348–6354
Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G (2009) Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 125:1372–1379
Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51:154–164
Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, Qian CN, Zeng YX (2010) Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 9:4
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274
Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L et al (2008) Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol 181:5842–5846
Gershon RK, Kondo K (1971) Infectious immunological tolerance. Immunology 21:903–914
Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723–737
Berendt MJ, North RJ (1980) T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69–80
Bursuker I, North RJ (1984) Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 159:1312–1321
North RJ, Bursuker I (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159:1295–1311
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061
Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330–336
Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337–342
Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V et al (2003) Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 102:4107–4114
Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, Piazza F, Lederman S et al (2002) Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3:237–243
Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S et al (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339–1346
Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T et al (2005) Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 65:5020–5026
Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737–742
Weiner HL (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182:207–214
Wood KJ, Sakaguchi S (2003) Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3:199–210
Bach JF (2003) Regulatory T cells under scrutiny. Nat Rev Immunol 3:189–198
Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW et al (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303–310
Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303–1310
Read S, Malmstrom V, Powrie F (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192:295–302
McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16:311–323
Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135–142
Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911
Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389–400
Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352
Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 31:1247–1254
Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, Wei S et al (2004) Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64:8451–8455
Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941–952
Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238
Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794–802
Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G et al (2005) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202:919–929
Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM (2003) Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198:235–247
Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM (2004) CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199:1467–1477
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G et al (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886
Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ (2004) CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 173:7259–7268
Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172:5149–5153
Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM (2005) Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 201:127–137
Hawrylowicz CM, O'Garra A (2005) Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5:271–283
Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE et al (2005) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075–1085
von Boehmer H (2005) Mechanisms of suppression by suppressor T cells. Nat Immunol 6:338–344
de la Rosa M, Rutz S, Dorninger H, Scheffold A (2004) Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 34:2480–2488
Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ (2004) Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589–601
Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ (2005) Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174:1783–1786
Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762–774
Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML et al (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4:1206–1212
Wilke CM, Zou W (2011) T lymphocytes to IDO+ cells: check. Blood 117:2082–2083
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871–881
Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761
Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D et al (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267–5272
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612
Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099
Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404–4408
Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, Utsunomiya A et al (2004) Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 126:81–84
Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103:1755–1762
Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H et al (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444–1453
Gray CP, Arosio P, Hersey P (2003) Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res 9:2551–2559
Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4772
Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457–2464
Wilke CM, Wu K, Zhao E, Wang G, Zou W (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127:748–758
Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L et al (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67:8900–8905
Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423–5434
Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I, Cosci E et al (2007) Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18:1115–1122
Hussein MR (2006) Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol 87:163–176
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380
Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A et al (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902–911
Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465–472
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H (2008) Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 98:148–153
Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV (2009) Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 9:65
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C et al (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186–192
Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ (2009) Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137:1270–1279
Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D et al (2010) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126:2635–2643
Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH et al (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11:1467–1473
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV et al (2003) TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 9:1517–1527
Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP (2000) In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 183:601–609
Cannon MJ, O'Brien TJ (2009) Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther 9:677–688
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58
Nestle FO, Banchereau J, Hart D (2001) Dendritic cells: on the move from bench to bedside. Nat Med 7:761–765
Pardoll D (2001) T cells and tumours. Nature 411:1010–1012
Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:562–567
Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH (1997) Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159:4772–4780
Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL et al (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186:6905–6913
Scarpino S, Stoppacciaro A, Ballerini F, Marchesi M, Prat M, Stella MC, Sozzani S et al (2000) Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156:831–837
Vicari AP, Treilleux I, Lebecque S (2004) Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol 14:161–169
Schwaab T, Weiss JE, Schned AR, Barth RJ Jr (2001) Dendritic cell infiltration in colon cancer. J Immunother 24:130–137
Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J et al (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190:1417–1426
Palucka K, Ueno H, Fay J, Banchereau J (2011) Dendritic cells and immunity against cancer. J Intern Med 269:64–73
Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F et al (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037–1047
Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R, Jagannath S et al (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 203:1859–1865
Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, Terebelo HR et al (2007) CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 109:5002–5010
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F et al (2008) Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 68:7684–7691
Wan T, Liu JH, Zheng LM, Cai MY, Ding T (2009) Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma. Ai Zheng 28:323–327
Wu K, Kryczek I, Chen L, Zou W, Welling TH (2009) Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69:8067–8075
Goede V, Brogelli L, Ziche M, Augustin HG (1999) Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer 82:765–770
Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64:275–290
Vicari AP, Caux C, Trinchieri G (2002) Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 12:33–42
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13:265–270
Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M et al (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282–3289
Amann B, Perabo FG, Wirger A, Hugenschmidt H, Schultze-Seemann W (1998) Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br J Urol 82:118–121
Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N (1998) Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194:335–340
Valkovic T, Fuckar D, Stifter S, Matusan K, Hasan M, Dobrila F, Jonjic N (2005) Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma. J Cancer Res Clin Oncol 131:453–458
Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10:248–256
Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W (2011) Th17 cells in cancer: help or hindrance? Carcinogenesis 32:643–649
Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ (1997) The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185:1101–1111
Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S et al (2004) Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64:5535–5538
Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, Curiel TJ (2000) Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 165:4388–4396
Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A et al (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466–7474
Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T et al (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478–6487
Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204:1441–1451
Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, Berenzi A et al (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200:255–268
Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, Shepherd D et al (2003) Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 33:1052–1062
Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185:4977–4982
Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4:e6412
Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307
Ziegler SF (2007) FOXP3: not just for regulatory T cells anymore. Eur J Immunol 37:21–23
Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE (2009) In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 183:3195–3203
Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer T, Syrovets T et al (2009) Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 183:1838–1845
Kemp TJ, Moore JM, Griffith TS (2004) Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 173:892–899
Lundy SK. Killer B lymphocytes: the evidence and the potential. Inflamm Res 2009 58:347–57
Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J (1992) Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 12:1463–1466
Marsigliante S, Biscozzo L, Marra A, Nicolardi G, Leo G, Lobreglio GB, Storelli C (1999) Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Cancer Lett 139:33–41
Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52:715–738
Lee AH, Happerfield LC, Bobrow LG, Millis RR (1997) Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol 181:200–206
Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 98:12659–12664
Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169:2701–2711
Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63:3275–3280
Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T, Pinkus GS et al (2009) The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J Immunol 182:3310–3317
Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB (1999) Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 12:1050–1056
Tamiolakis D, Simopoulos C, Cheva A, Lambropoulou M, Kotini A, Jivannakis T, Papadopoulos N (2002) Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Eur J Gynaecol Oncol 23:433–436
Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169:1829–1836
Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:5405–5413
Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V (1977) Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 40:1365–1385
Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R (2010) Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun 10:3
Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E et al (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res 71:3505–3515
Riemann D, Wenzel K, Schulz T, Hofmann S, Neef H, Lautenschlager C, Langner J (1997) Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Int Arch Allergy Immunol 114:38–45
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N et al (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417
Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220–5227
Yasuda M, Mizukami M, Hanagiri T, Shigematsu Y, Fukuyama T, Nagata Y, So T et al (2006) Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer. Anticancer Res 26:3607–3611
Nedergaard BS, Ladekarl M, Nyengaard JR, Nielsen K (2008) A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol Oncol 108:106–111
Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B et al (2006) NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125:451–458
Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678–1685
Stashenko P, Nadler LM, Hardy R, Schlossman SF (1981) Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA 78:3848–3852
Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF, Nadler LM (1983) Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol 131:232–237
Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131:244–250
Watt V, Ronchese F, Ritchie D (2007) Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother 30:323–332
Rodriguez-Pinto D (2005) B cells as antigen presenting cells. Cell Immunol 238:67–75
Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL et al (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1:475–482
Lund FE, Cytokine-producing B (2008) lymphocytes-key regulators of immunity. Curr Opin Immunol 20:332–338
Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Voss CY, Klein H et al (2008) Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 180:1362–1372
Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MJ, Ahmed R (2009) Requirement of B cells for generating CD4+ T cell memory. J Immunol 182:1868–1876
Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF (2008) B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:284–299
Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180:5771–5777
Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043–1051
Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M (2009) Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:1178–1184
Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, Zou W (2012) Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 72:420–429
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wilke, C.M. et al. (2013). T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment. In: Curiel, T. (eds) Cancer Immunotherapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4732-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4732-0_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4731-3
Online ISBN: 978-1-4614-4732-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)